by Stephen Levin
The current excitement surrounding the early success of drug-eluting stents represents the latest episode in the ongoing debate about whether...
Ron Matricaria: A Study in Conviction
Not many healthcare product executives have resumes that can boast of having run both drug and device businesses the way Ron Mstricaria did at Eli Lilly. Not content with his success at Lilly, Matricaria took early retirement to embark on the challenge of directing St. Jude Medical's transition from a successful single-product firm to a major, multi-platform device company. At both companies, Matricaria endured tough times and critics questioning his strategies, but was ultimately vindicated through the success of each company. Matricaria is the recipient of this year's Phoenix Lifetime Achievement award and spoke with IN VIVO about his career and the current state of the medical device industry.
More from Business Strategy
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.